FRANKFURT (Reuters) – German healthcare group Fresenius said its generic drugs unit Kabi has agreed to acquire a 55% stake in mAbxience Holding S.L. for 495 million euros ($553 million) plus milestone payments contingent on commercial and development targets.
Fresenius will also have an option to buy the remaining shares in mAbxience, a maker of biosimilar drugs without patent protection, under certain terms.
In a statement on Thursday, Fresenius said the Kabi division also agreed to acquire Ivenix Inc, a maker of infusion therapies, for $240 million upfront plus milestone payments.
($1 = 0.8955 euros)
(Reporting by Ludwig Burger, Editing by Miranda Muray)
